Perceptions and Representations of Vaccination Against COVID-19

NCT04896957•Centre Hospitalier Intercommunal Creteil

Summary

SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high: According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19. To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Over 18 years of age
•Patient with a scheduled appointment in consultation or at the vaccination centre
•Not opposed to participation in the protocol

Exclusion Criteria

•Patient under guardianship or curatorship
•Patient unable to give free and informed consent
•Patient under court protection
•Patient without the cognitive capacity to ensure an interview

Locations (1)

CHI Villeneuve-Saint-Georges

Villeneuve-Saint-Georges, France

Key Dates

Start Date

September 1, 2021

Primary Completion Date

September 1, 2022

Completion Date

September 1, 2022

Last Updated

December 2, 2022

Enrollment

ACTUAL participants

Conditions

COVID-19 Acute Respiratory Distress Syndrome

Interventions

Interview

BEHAVIORAL

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

NCT04896853

COVID-19 Acute Respiratory Distress SyndromeInfluenza A+2 more

View study

COMPLETEDNA

Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19

NCT04922814

COVID-19 Acute Respiratory Distress SyndromeSedation Complication+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Perceptions and Representations of Vaccination Against COVID-19

Inclusion Criteria

Exclusion Criteria

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19

Cerebral Autoregulation and COVID-19

Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)

T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19

Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress Syndrome